Background: The American Diabetes Association task force on standardization of insulin assays in 1996 showed wide variation in assay bias. Newer assays are specific for insulin, with several now available on automated immunoassay analyzers. Methods: In 2004, we compared 11 commercially available insulin assays by analyzing 150 serum samples (99 fasting/51 postprandial) from study participants with various degrees of glucose intolerance (exclusions being type 1 diabetes, insulin treatment, or presence of insulin antibodies). All assays were calibrated against International Reference Preparation 66/304. One assay was not specific for insulin and another was an RIA; 10 assays used enzyme/chemiluminescent labels. Bland-Altman difference plots were modified to use the mean insulin from all assays on the x-axis as a common comparator. Results: As in the 1996 study, insulin values from the different assays varied by a factor of 2, with the nonspecific assay ranking in the middle of the distribution. Spearman rank correlation coefficients, for ranking samples vs the mean, were 0.983-0.997. Both offsets and concentration-dependent differences were seen in the modified difference plots. Imprecision (mean CV) for automated assays (3%) was not significantly different from the mean CV for manual assays (5%). Similar values were obtained when one automated assay was run in laboratories in both the UK and the US.Results of 1 assay showed lower insulin concentrations in heparinized plasma than in serum.
added human recombinant insulin was 274 pmol/L, range 160 -475 pmol/L (Gwen Wark, personal communication, March 7, 2006) . Specificity, sensitivity, and working ranges are key issues for measurement of circulating insulin for the clinical investigation of hypoglycemia (7 ) . Calculated indices such as those derived from Homeostasis Model Assessment (HOMA) for insulin resistance and ␤-cell function, widely quoted in research, are dependent on the absolute value for insulin and on specificity in particular (16 ) .
We compared commercially available insulin assays by assaying serum samples from study participants with varying degrees of glucose tolerance.
Materials and Methods
In this study, performed in 2004, insulin concentrations in fasting and postprandial serum samples from study participants with varying degrees of glucose tolerance were measured by use of 11 insulin assays performed in 7 UK and 2 US laboratories. Reconstituted, lyophilized QC material was also circulated. Total proinsulin was measured in one center, insulin compared in serum and heparinized plasma in another, and the same assay compared in 2 laboratories in the UK and US.
Ethics approval was obtained from the South East Wales Local Research Ethics Committee and complies with the current revision of the Helsinki Declaration.
patients
Fasting or postprandial blood samples were collected from 138 participants, 18 -75 years of age. Sample donors were either nondiabetic or had impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes. Patients with type 1 diabetes or type 2 diabetes requiring insulin treatment or who were recorded as insulin antibodypositive were excluded. Anonymized data were collected, including age, ethnicity, height, weight, and whether the sample was taken fasting or postprandial. All patients gave written informed consent.
The 150 blood samples (fasting/nonfasting 99/51) were collected from 43 healthy persons (fasting/nonfasting 14/29), 20 patients with impaired fasting glucose or impaired glucose tolerance (fasting/nonfasting 18/2), and 87 patients with type 2 diabetes (fasting/nonfasting 67/20). Both fasting and nonfasting samples were obtained from 12 study participants. The mean (SD) age and body mass index of the normoglycemic study participants were 43.8 (14.3) years and 28.5 (6.2) kg/m 2 . The corresponding values for those with impaired fasting glucose or impaired glucose tolerance were 62.0 (10.1) years and 31.0 (4.9) kg/m 2 , and for those with type 2 diabetes 60.0 (9.4) years and 31.9 (5.6) kg/m 2 .
collection of blood 
insulin and proinsulin assays
Study organizers selected the most commonly used, commercially available insulin assays from those used by participants in the UK NEQAS Guildford. Assay information obtained from the manufacturers is shown in Table 1 . Manual and automated assays for clinical investigation and research were included; some were approved for research use only. Assays from the US were included, one from the previous comparison (1 ) and another used for major epidemiological studies (17, 18 ) . The Tosoh ST AIA assay was included twice, once from a US research laboratory and once from a routine UK hospital laboratory. All laboratories requested serum when given the option of serum or heparinized plasma. 
Results insulin assays
Serum was assayed in 7 UK and 2 US laboratories between May and July 2004 with commercial insulin assays ( Table 1) described by the manufacturer as standardized against the first International Reference Preparation 66/304 (IRP 66/304). Eleven immunometric assays using various separation and detection systems were included, i.e., 4 immunoenzymometric assays, 2 immunochemiluminometricassays, 1 immunoelectrochemiluminometric assay, 3 ELISAs, and 1 RIA. Only the ELISA from Mercodia was not specific for insulin, showing 54% cross-reactivity with intact proinsulin (manufacturer's data). Six assays were run on automated, high-throughput immunoassay analyzers used in routine clinical laboratories, and 6 were run manually. Sample volume varied from 20 to 100 L, not including dead volume for sampling with automated analyzers or the volume for duplicate assay if recommended by the manufacturer. Sensitivity, as stated by the manufacturers, ranged from 0.7 to 12 pmol/L. Some manufacturers provided details on the experiment used to determine sensitivity; it was usually determined by replicate analyses of a matrix material free of insulin. The mean of the zero signal plus 2 SD was used for 6 assays and mean plus 2.5 SD for another, but was not defined for the others. The upper concentration limit above which dilution was recommended ranged from 600 to 6945 pmol/L. Conversion factors, from mIU/L to pmol/L, varied from 6 to 7.46; Tosoh updated its conversion factor from 6 to 7.17 in July 2006.
assay imprecision
Imprecision, the mean of CVs for trilevel QC analyzed on 5 days, varied from 1.4% for 1 automated assay to 6.7% for Table  2 ). The source of insulin (bovine or recombinant human) was not stated by the manufacturer of the QC materials.
insulin measurement in heparinized plasma and serum 
insulin and proinsulin
Insulin results for serum from the different assays varied by a factor of 2 for median and maximum values ( Table 2) . The median and maximum values for the nonspecific assay ranked in 7th place (starting with the lowest value). Minimum values for insulin in human samples varied by a factor of Ͼ20 (Table 2) , with values of Ͻ10 pmol/L obtained from 2 automated assays (Tosoh and Roche) and the nonspecific ELISA (Mercodia), and from 11.5 to 38 pmol/L for the others. Spearman correlation coefficients (r 2 ) vs the mean ranged from 0.983 to 0.997 (Table 3) . Similar results were obtained when serum was run on the same automated assay (Tosoh) in 2 laboratories ( Table 2) . The results fell on or around the line of identity, with a mean difference of 1.92 pmol/L (95% CI Ϫ0.12 to 3.97), P ϭ 0.0647, (Fig. 2) . Total proinsulin ranged from 2 to 168 pmol/L with median (IQ range) 23 (12-43) pmol/L.
difference plots
The modified difference plots (Fig. 3) and usual difference plots (see Figs. in the online Data Supplement) showed constant differences or differences that were proportional to the concentration. The difference plots for one assay vs another, available electronically, validate the use of the mean value for a common x-axis and will be of interest to laboratories running a particular assay/s. The slope and intercept for differences vs the mean are presented in Table 3 as linear regression equations A, and for insulin values vs mean (scattergrams not shown) in Table 3 as B. Marked differences from the means were found for manual assays from Linco ELISA and Dako, with slopes of Ϫ0.32 and Ϫ0.20 (Table 3A) , with the Linco RIA giving higher results, slope 0.19. The BiosourceInvitrogen assay that did not report results Ͻ38 pmol/L showed high concentration-dependent differences, as did the Mercodia ELISA that was reported to cross-react with total proinsulin, whereas the other 2 ELISAs had negative concentration-dependent differences. The MLT assay showed an offset with an intercept of Ϫ17 pmol/L. Of the automated assays, Abbott AxSYM and Bayer Advia Centaur showed positive, concentration-dependent differences (N.B., conversion factors Ͼ6.0), the DPC Immulite 1000 showed negative differences, and the Roche Elecsys E170 and Tosoh ST AIA had results closest to the mean of the assays.
Discussion
Since the ADA report on insulin standardization in 1996 (1 ), specific insulin assays have been introduced that incorporate nonradioisotopic labels and are suitable for automated platforms. In this comparison of 11 insulin assays, values measured for serum varied by a factor of 2, as reported earlier (1 ). However, progress with an international reference method and preparation has been slow, although recently mass spectrometric methods for insulin have been described (23 ) .
Specificity of assays, calibration procedures, specimen type, assay performance, and conversion factors may all contribute to interassay variation. In this study, total proinsulin concentrations were in accord with previously published reports of 10% (proinsulin:insulin) for samples from persons without diabetes and 20% for patients with type 2 diabetes (24 ), with no samples displaying inappropriate hyperproinsulinemia (25 ) . All assays except 1 were reported by manufacturers to be specific for insulin, and 1 was a specific RIA (Linco) that was included in the previous ADA comparison. The TOSOH assay, run in the US and UK for this study, produced similar results in the different laboratories, in contrast to the previous ADA comparison. In US epidemiological studies this assay was chosen recently to replace the nonspecific Pharmacia RIA100, which had been withdrawn because antibody stocks were exhausted. The nonspecific assay (Mercodia Iso-Insulin) ranked in the middle of the distribution of the assays in this study. This manufacturer, Mercodia, also produces a specific insulin assay with no detectable cross-reactivity with proinsulin and does 31-21 and 32-33 split proinsulins.
All manufacturers reported that their assays were calibrated against the same insulin reference preparation (IRP 66/304) prepared from human pancreas with a stated number of units per ampule. Details of manufacturers' calibration procedures and calibrants (26 ) were not requested by the authors. Mean (range) recovery of IRP 66/304 in 14 methods has been reported to be 89% (75% to 127%), (27 ) . Some assays showed overrecovery (Abbott AxSYM 127%), some underrecovery (DPC Immulite 75%), and some had recoveries within 10% (Bayer Centaur 100%, Dako 91%, Mercodia ELISA 99%, MLT 98%, and Roche Elecsys 103%). It remains to be seen whether the use of a human recombinant insulin preparation, calibrated in molar and mass terms, will reduce the interassay variability.
All participating laboratories measured insulin in serum, although heparinized plasma was also available. For illustrative purposes, both sample types were compared in 1 assay, and in that case higher insulin values were obtained in serum. Because these differences may be assay specific, individual laboratories should confirm with the assay manufacturer the procedures recommended for specimen collection and compare results for plasma and serum as required (28 ) . The differences observed could be clinically significant when insulin concentrations or derived mathematical functions are compared for patient care or research.
Five assays were run on automated analyzers, and no significant difference in imprecision was observed between automated and manual assays. Bias and imprecision for lyophilized QCs in the individual assays did not always mirror those seen in serum (Table 2) , an important point for external quality assessment schemes. The use of nonhuman insulin in QCs and matrix effects may explain these differences. Although the security of baseline or low concentrations is important (28 ) , sensitivity, as reported by the manufacturers, was determined in a number of ways that were not comparable. Use of the minimum detectable concentration from precision profiles may yield more reliable estimates.
A conversion factor of 6 for recombinant human insulin has been reported (1, 29 ) . In this study, however, the conversion factors used by the manufacturers were found to vary considerably, with the potential to influence insulin values by up to 15%. For 3 of 4 specific assays using conversion factors Ͼ6, reported mean values were in the top half of the distribution, and the other value was in the middle. Assays using a factor of 6 ranked mainly in the bottom half, except for the specific RIA (Linco) that gave the highest results. Interestingly, an ELISA from the same company, also using 6 as a factor, gave the lowest results. Because of potential assay interference, our study has limitations that prohibit the extrapolation of results to patients with insulin antibodies. The results are also not applicable to patients treated with insulin analogs, because these cannot be detected with some specific insulin assays (11) (12) (13) (14) . A limited number of batches of reagent and calibrators were used in this study. Because there is no reference method for insulin or consensus on standard statistical techniques for such multiassay analyses (30 ) , the mean insulin value for each sample was used as a common comparator. This approach may not be appropriate for a smaller number of assays.
Various techniques have been used over the years for comparing measurements from different studies and for reducing assay variation. For major research studies, insulin has been measured in central laboratories (3 ) . In some studies data have been divided into ranks, but this method may not be reliable because populations differ (31 ) , and it is not helpful when considering individuals. Results for other analytes such as hemoglobin A 1c have been aligned to those reported by major clinical trials while the international reference method was being evaluated (32 ) . In the case of human chorionic gonadotropin, clearly defined calibration procedures for the international standard and careful selection of antibodies reduced assay variation (33 ) . Intermethod differences of 2-to 5-fold in prostate-specific antigen measurement results (34 ) were eliminated by the introduction of standard calibrators and guidelines, but differences in the recovery of international standards on automated platforms still varied by Ϫ5% to ϩ22%. These results may be related to data transfer between the primary standards and master calibrator, and between master calibrator and individual reagent set calibrators, a potential issue for all analytes.
International diabetes and clinical chemistry organizations should be aware of the need for comparability of insulin values for patient care, clinical research studies, and any resulting metaanalyses or clinical research networks (35 ) . Clinicians and researchers should be made aware of the fact that serum insulin measurements from the various assays now available can differ by a factor of 2. 
